Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

Sachin stability and ich

102 vues

Publié le

stability guideline

Publié dans : Sciences
  • Visit this site: tinyurl.com/sexinarea and find sex in your area for one night)) You can find me on this site too)
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • Sex in your area for one night is there tinyurl.com/hotsexinarea Copy and paste link in your browser to visit a site)
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • Girls for sex are waiting for you https://bit.ly/2TQ8UAY
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • Meetings for sex in your area are there: https://bit.ly/2TQ8UAY
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici
  • Best site for flirting and sex in your area you can find there: https://bit.ly/2SlcOnO
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici

Sachin stability and ich

  1. 1. Seminar on Basic concept and objective of Stability studies PRESENTED BY: Sachin. S .Bhagat M.pharm (pharmaceutics) Roll no :13 GUIDED BY- Dr.D.V Derle (principal) MVP Samaj’s College Of Pharmacy, Nashik. .
  2. 2. Contents. • Introduction • Factors affecting stability • Types of stability • Objective of stability • Types of stability study • ICH Guideline of stability study • Climatic zone • Steps of stability testing • Reference
  3. 3. Introduction : • Drug stability refers to capacity of drug substance or product to remain within specification of identity, strength, quality and purity in specific period of time • Stability is officially define as time lapse during which the drug product retain the same properties and characteristics that it possessed at time of manufacture • The stability of a product is expressed as the expiry period or technically as shelf life
  4. 4. Shelf life. • It is defined as the time required for the concentration of drug/reactant to reduced to 90% of its initial concentration • It represent as t90 • Unit : time/sec • Formula : t90 =(a-0.9a)/k0 Where , a= initial concentration k= specific rate constant for zero order reaction
  5. 5. Factors affecting Drug stability: Primary factors: • pH • Temperature • Moisture • Humidity • Light • Container and closure • Storage
  6. 6. Secondary factors: • Particle size (suspension and emulsion) • Molecular binding • Diffusion of drug and excipient
  7. 7. Types of stability • Therapeutical stability : therapeutic activity must be unchanged • Chemical stability : chemical must be in pure form • Microbiological stability : resistance to microbial growth • Toxicological stability : no significant change • Physical stability :appearance, palatability ,uniformity & suspend ability
  8. 8. what happen due to instability: 1)increase in concentration of API: for some product ,loss of vehicle can result in an increase in concentration of active drug. e.g. : lidocaine gel - perfusion bag sometime allow solvant to evaporate so product within bag show an increase in concentration. 2)loss of content uniformity : Suspension are the drug delivery system most likely to show content uniformity as a function of time and for stability of such product sedimentation volume and ease of redispersion should determine . 3)decline microbiological status : Microbiological status of pharmaceutical can decline with time prevention: drug assay for bioburden at time of manufacture, within limit, and when tested after say 6 month storage exceed the maximum permitted limits
  9. 9. 4) formation of toxic degradation product : If drug degrade to molecular species that is toxic ,there must be special attention given to the quantity of such product e.g conversion of p-amino salicylic acid to p- amino phenol Objective of stability testing : 1)concern for patient welfare : primary reason for stability testing should be our concern for the well-being of patient who will use our product 2) To protect the reputation of the producer: The most important reason for conducting a stability testing program is to assure ourselves the our product will indeed retain fitness for the use with respect to all functionally relevant for along as they are on the market
  10. 10. 3)To check shelf life & storage condition & labelling specification : By carrying out stability testing we can find out the shelf life and expiry date. We can have information of best storage condition at which drug will contain its stability for long time If their is specification we can write on label 4) Adequate formulation &container closure system: We can have idea about the formulation which will be more stable .and if during stability testing we find any specification of container E.g : menadione injection packed in amber color ampoule to protect from photo degradation 5)How quality of drug substance or product varies with time under influence of various factor 6) degradation of product& and possible degradation pathway
  11. 11. 7) Prevent great loss by recalling the batch due to stability 8)loss and increase in concentration of API 9) providing evidence on how quality of drug substance or product varies with time under the influence of various factors like temperature, humidity and light 10) loss of pharmaceutical elegance and patient acceptability
  12. 12. Guidance and requirement for stability study covered in : 1) international conference on harmonization (ICH) 2) WHO guideline for stability testing 3) US-FDA guideline 4) SUPAC guideline scale-up and post approval changes
  13. 13. Types of stability studies : 1) accelerated stability testing 2) intermediate stability testing 3) long term testing 4)degradation testing 5) photo stability testing
  14. 14. ICH guideline for stability testing : ICH GUIDELINE TITLE Q1A Stability testing of new drug product and substance Q1B Stability testing : photo stability testing of new drug product and substance Q1C Stability testing for new dosage form Q1D Bracketing and matrixing designs for stability testing of drug substance and product Q1E Evaluation of stability data Q1F Stability data package for registration application in climatic zone III and IV
  15. 15. Climatic zones : ZONES CLIMATE Storage condition ZONE I Temperate 21 C/45% RH ZONE II Subtropical and high humid 25 C/60%RH ZONE III Hot & dry 30 C/35%RH ZONE IV Hot & humid 30C/70%RH
  16. 16. Steps of stability testing : 1) selection of batches 2) Testing frequency 3) Storage condition 4) Acceptance criteria 5) Evaluation 6) Labelling
  17. 17. SELECTION OF BATCHES: 1)Stability information from accelerated & long term stability should provided on batches Of same formulation & dosage form in container and closure purpose of manufacture 2)stability data of 3 primary batches should provided 3) expected that at least first 2 batches of manufacture should be tested for long term stab 4)the composition ,batch size, batch no & manufacturing date should documented
  18. 18. TESTING FREQUENCY: According to ICH Stability testing Testing interval Real time testing (Q1) 0,3,6,9,12,24 Month Accelerated testing 0,3& 6 month Intermediate 0,6,9& 12 month • For accelerated testing ,FDA suggest : 0,2,4& 6month WHO suggest :0,1,2,3&6 month • FDA & WHO do not suggest for intermediate testing
  19. 19. Storage condition : According to Q1A &Q1F ZONE I &II Temperature RELATIVE HUMDITY Time Long term study 25℃ +2 60% + 5 12 month Intermediate study 30℃ + 2 65% + 5 6 month Accelerated study 40℃+ 2 75% + 5 6 month ZONE III &IV Temperature Relative humidity Long term 30℃+2 65% +5 Accelerated 40℃+2 75% +5
  20. 20. Acceptance criteria : Significant change for a drug substance is defined as failure to meet its specification 1) A 5% potency loss from initial assay value of a batch 2) Any specified degrading exceeding its specification limit 3) The product exceeding the pH limit 4) Dissolution exceeding specification limit for 12 capsule or tablet 5) Failure to meet specification for appearance and physical properties (e.g , color ,phase separation , caking, hardness, resuspendability 6) 5% loss in water from its initial value form packaged in semi permeable container
  21. 21. Evaluation 1) tabulate and plot stability data on all attributes at all storage condition and evaluate each attribute separately 2) No significant change at accelerated condition within six month 3) Long term data show little or no variability and little or no change over time
  22. 22. Labelling : 1)Use of term such as “ ambient condition ’ or “ room temperature” is unacceptable 2) where applicable , specific requirement should be stated e.g. “protect from sunlight” ,”protection from freezing” the use of precautionary statement should not be substituted 3)normal storage condition have been defined by WHO as “store in dry , well ventilated premises at temperature of 15 - 25 ℃ . 4) store in refrigeration , no freezing ( 2& 8 ) 5) in deep freezer (-18. ) 6) In freezer (-5 to 20 )
  23. 23. REERENCE : 1) Drug stability : principles and practices ,1st Edition, edited by Jens T. Carstensen and C.T. Rhodes (Marcel Dekker Inc, New York ,1990) 2) Textbook of physical pharmacy by C.V.S Subrahmanyam published by M.K jain for Vallabh prakashan 5th edition 2004 3) http://pharmaquest.weebly.com/uploads/9/9/4/2/9942916/basic_concept _of_stability_studies.pdf

×